

## 20<sup>th</sup> WOAHA/FAO FMD Reference Laboratories Network Annual Meeting

23<sup>rd</sup>-24<sup>th</sup> October 2025

Hosted by the Şap Institute, Türkiye at the Sheraton Istanbul City Centre

### Joining details for virtual attendees:

**23/10/25**

Microsoft Teams [Need help?](#)

[Join the meeting now](#)

Meeting ID: 386 178 174 025 0

Passcode: M448S9wN

#### Join on a video conferencing device

Tenant key: [113787524@teams.bjn.vc](mailto:113787524@teams.bjn.vc)

Video ID: 129 960 857 2

[More info](#)

For organizers: [Meeting options](#)

**24/10/25**

Microsoft Teams [Need help?](#)

[Join the meeting now](#)

Meeting ID: 349 024 120 848 4

Passcode: St3uS9AW

#### Join on a video conferencing device

Tenant key: [113787524@teams.bjn.vc](mailto:113787524@teams.bjn.vc)

Video ID: 125 621 463 3

[More info](#)

For organizers: [Meeting options](#)

### Attending in person:

- Şap Institute, Türkiye - Abdulnaci Bulut and Can Cokcaliska
- Sciensano, Belgium - David Lefebvre and Anne-Sophie Bultinck
- Botswana Vaccine Institute, Botswana – Elliot Fana
- National Centre for Foreign Animal Disease, Canada - Shawn Babiuk
- LVRI, China - Haixue Zheng, Wen Dang, Jijun He and Zixiang Zhu
- ANSES, France - Guillaume Girault, Sandra Blaise-Boisseau
- IZSLER, Italy - Santina Grazioli, Efrem Foglia and Tiziana Trogu
- APQA, Republic of Korea - Su-Mi Kim and Soyeon Ryoo
- Onderstepoort Veterinary Institute (OVI), South Africa - Melanie Chitray
- The Pirbright Institute, UK - Donald King, Anna Ludi, Antonello Di Nardo and Andrew Shaw
- WUR, Netherlands – Phaedra Eble
- RRLSEA, Pakchong, Thailand - Kingkarn Boonsuya Seeyo
- FMD Reference Laboratory, Embakasi, Kenya – **Kenneth Ketter (tbc)**
- Animal Health Institute (AHI), Ethiopia – Daniel Gizaw (tbc)
- National Veterinary Research Institute (NVRI), Nigeria – **Hussaini Ularamu (tbc)**

- National Institute of Animal Health (NIAH), Japan - Kazuki Morioka, Katsuhiko Fukai
- FLI, German FMD NRL – Michael Eschbaumer
- CSIRO, Australia – Wilna Vosloo
- Labib Bakkali Kassimi
- WOA – Min-Kyung Park
- FAO – Nick Lyons, Fabrizio Rosso (EuFMD)
- Boehringer Ingelheim - Pascal Hudelet and Amelie Poulard
- Biogénesis Bagó - Romina Scian and Sabrina Cardillo
- Dollvet - Sinan Aktas and Yaser Vezir
- MSD (Merck) - Chriche du Plessis

*Other representatives will join the meeting virtually:*

- PANAFTOSA-PAHO/WHO, Brazil - Edviges Maristela Pituco and Euclides José de la Torre Medranda
- SENASA, Argentina – Sabrina Galdo
- Botswana Vaccine Institute, Botswana – Joseph Hyera
- US Department of Agriculture (USDA), USA – Vivian O'Donnell and Amanda Kortum
- ICAR NIFMD, India – Rabindra Prasad Singh
- Wageningen Bioveterinary Research (WBVR), Aldo Dekker
- FAO, Artem Metlin, Estelle Kanyala, Austine Bitek and Lisette Kohagne
- RESEPI-CA, Cameroon, Jean Marc Feussom
- Lab MENET, Egypt, Ahmed R. Habashi
- Zimbabwe, Pious V Makaya
- Representative from AHRI, Egypt
- Şap Institute, Türkiye – Ünal Parlak
- Chief Director of Veterinary Services, Zimbabwe – Pious Makaya

## DRAFT AGENDA

| Thursday 23rd October                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 08:30                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                 |
| Item 1                                                                                                                                                                                                                                       | Opening talk for the GFRA “Hybrid” – Diagnostics and Epidemiology<br>Brief overview of the Network activities and achievements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Don King                                                                                                                                                        |
| 12:45-13:30 Lunch                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                 |
| Mardin Meeting Room ( <b>on-line session starts here</b> )<br>13:30 UTC +3                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                 |
| Item 2                                                                                                                                                                                                                                       | [a] Brief review of meeting agenda<br>[b] Feedback and priorities from WOAH, FAO and EuFMD<br>All partners prepare a 10min (max) talk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Min Park<br>Nick Lyons<br>Fabrizio Rosso                                                                                                                        |
| Item 3                                                                                                                                                                                                                                       | Laboratory updates (activities and FMD intelligence for 2025)<br>Laboratory partners are requested to prepare a 15 min (max) presentation according to the template provided to focus on FMD samples tested and epidemiology events during 2025                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Chaired by: David Lefebvre<br><b>ALL</b>                                                                                                                        |
| 15:30-15:45 Break                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                 |
| Item 4                                                                                                                                                                                                                                       | Review of global FMD risks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Chaired by: Melanie Chitray<br><b>ALL</b>                                                                                                                       |
| Sponsored dinner – (Location Has Salon Restaurant at the Biz<br><a href="https://www.bizistanbul.com.tr/en/hassalon">https://www.bizistanbul.com.tr/en/hassalon</a> , 19:00) – NB: we are planning to walk to this restaurant from the hotel |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                 |
| Friday 24 <sup>th</sup> October                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                 |
| Start at 8:30                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                 |
| Item 5                                                                                                                                                                                                                                       | OpenFMD – improving the depth of data collated by the Network                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Chaired by: Shawn Babiuk and Guillaume Girault (tbc)<br><br>Antonello Di Nardo                                                                                  |
| Item 6                                                                                                                                                                                                                                       | Network work plan for 2026 - points for discussion/agreement<br>(i) Management of the Network (membership and coordination)<br>(ii) Update on Actions from previous meetings<br>(iii) Proposed updates to the WOAH Manual (focussing on the vaccine sections)<br>(iv) Defining protected and non-protected animals in official texts for vaccine potency ( <b>for agreement</b> )<br>(v) Perspective: From bench to market - translating basic research into development of new FMD vaccines<br>(vi) Role of reference laboratories to verify the quality of FMD vaccines (guidelines to outline how sera should be submitted to assess vaccine quality and how these data should be presented)<br>(vii) Feedback from the WOAH disease Networks meeting in May 2025 <a href="https://www.woah.org/en/strengthening-collaboration-across-our-reference-centre-network/">https://www.woah.org/en/strengthening-collaboration-across-our-reference-centre-network/</a><br>(viii) Availability of reference reagents for FMD diagnostics, for guidance see: <a href="https://www.woah.org/en/what-we-offer/veterinary-products/#ui-id-4">https://www.woah.org/en/what-we-offer/veterinary-products/#ui-id-4</a> | -WRLFMD<br><br>-Anna Ludi<br>-Working group<br>-Document circulated<br>-LVRI<br><br>Commercial sector and all lab partners<br>-Labib Bakkali<br>Kassimi<br>-ALL |

|                       |                                                                                                                                                                                                                                                                                                                                                                                                                             |           |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
|                       | (ix) Preparation of draft guidelines to outline the use of pen-side (devolved) tests for examples, see: <a href="https://rr-asia.woah.org/en/news/the-oie-asf-reference-laboratory-networks-overview-of-african-swine-fever-diagnostic-tests-for-field-application/">https://rr-asia.woah.org/en/news/the-oie-asf-reference-laboratory-networks-overview-of-african-swine-fever-diagnostic-tests-for-field-application/</a> | -ALL      |
|                       | (x) Update on the Nagoya Protocol                                                                                                                                                                                                                                                                                                                                                                                           | -Don King |
| 10:00-10:15           | Break                                                                                                                                                                                                                                                                                                                                                                                                                       |           |
| Item 6                | Continued                                                                                                                                                                                                                                                                                                                                                                                                                   |           |
| 12:00-12:45           | Lunch                                                                                                                                                                                                                                                                                                                                                                                                                       |           |
| Item 6                | Continued                                                                                                                                                                                                                                                                                                                                                                                                                   |           |
| Close (approx. 14:00) |                                                                                                                                                                                                                                                                                                                                                                                                                             |           |

Thank you to our sponsors:

Gold:



Silver:

